Mark Smythe, PhDFounder and Vice President at Protagonist Therapeutics
Mark Smythe, Ph.D.—Mark is the founder of Protagonist and has served various senior roles since 2001. He is also a Group Leader at the Institute for Molecular Bioscience, The University of Queensland. Mark earned a Ph.D. in Medicinal Chemistry from Melbourne University and a B.Sc (Hons) in Synthetic Organic Chemistry from James Cook University. Mark has significant commercial research experience and has been involved in translating platform discovery companies into clinically focussed enterprises. Mark’s research interest are around exploiting novel chemical modalities to address difficult targets and unmet medical needs underpinning patient need. He has been involved in the discovery of one marketed drug and three candidates currently in clinical trials.